Phase II study of Glypican-3(GPC3) peptide vaccine as treatment for clear cell adenocarcinoma of ovary.
Phase 1
Recruiting
- Conditions
- clear cell carcinoma of ovary
- Registration Number
- JPRN-UMIN000003696
- Lead Sponsor
- Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1 Uncontrolled pleural effusion or ascites 2 There are other malignancies. 3 Active infection excluding HBV,HCV 4 Positive for HIV 5clinically significant heart disease angina within the past six months, or uncontrolled Diabetes Mellitus 6There is severe psychiatric disorder 7Pregnant or lactaing woman,who are willing to be pregnant 8Past history of severe drug allergy 9Immunodeficiency, previous splenectomy,irradiation to the spleen 10Ongoing treatment with corticosteroid or immnosuppresant drug 11Previous allogrant transplantation 12 Responsible doctors juged the patient in appropriate for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method